The management team have extensive knowledge of histology, immunohistochemistry and image analysis techniques and have considerable experience in the development and integration of translational biomarker strategies into drug discovery programs.
Chief Scientific Officer & Founder
Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.
Chief Operations Officer & Founder
John worked for a total of 15 years as a biology project leader for various pharmaceutical companies including AstraZeneca and Merck & Co. He has expertise in the integration of translational biomarkers into drug discovery programs and has considerable experience in developing in vitro, ex vivo and in vivo models involving image analysis across numerous therapeutic areas. He is a Prince2®-practitioner qualified project manager.
Senior Project Manager
Mark worked in the pharmaceutical industry for 30 years (Organon, Schering-Plough, Merck & Co.) using techniques such as in-situ hybridisation, histology and immunohistochemistry, image analysis and the Affymetrix platform. More recently, Mark was a team manager and study director with global responsibility for supporting and developing pre-clinical safety studies at Charles River.
Clinical Operations Manager
Alison Bigley is a Fellow of the Institute of Biomedical Science and spent 25 years at AstraZeneca as an Associate Principal Scientist and Team Leader in Pathology. She established and led a global digital pathology platform which included programming in proprietary software, application development and GxP validation. Alison has considerable experience in histology, immunohistochemistry and imaging on projects across various therapeutic areas involving pre-clinical, safety and translational medicine.
Senior Business Development Manager
Keith has worked in the Pharmaceutical industry for over 25 years, with experience in large Pharma (AstraZeneca), Biotech (Mironid) and the contract services sector (Biopta & OracleBio). He has held positions of both scientific, project and people leadership, with experience across the drug Dx/Dv pipeline, from HTS to through to early clinical development support, including biomarker and translational science studies.
OracleBio's Quantitative Digital Pathology Services
Reasons Why Our Clients Choose to Work With OracleBio
Stay up to date with OracleBio
Subscribe to our mailing list to stay informed about news, webinars, events and more